Jasper Therapeutics, Inc. (NASDAQ:JSPR) Sees Large Growth in Short Interest

Jasper Therapeutics, Inc. (NASDAQ:JSPR) saw a large growth in short interest during the month of July. As of July 31st, there was short interest totaling 4,311,877 shares, a growth of 159.5% from the July 15th total of 1,661,803 shares. Based on an average trading volume of 4,576,589 shares, the short-interest ratio is presently 0.9 days. Approximately 15.8% of the shares of the stock are sold short.

Jasper Therapeutics Price Performance

Jasper Therapeutics stock traded down $0.07 during midday trading on Friday, reaching $0.79. The stock had a trading volume of 567,510 shares, compared to its average volume of 2,265,872. Jasper Therapeutics has a twelve month low of $0.32 and a twelve month high of $3.14. The firm has a market cap of $22.12 million, a price-to-earnings ratio of -0.24 and a beta of 3.02. The firm’s fifty day simple moving average is $0.59 and its two-hundred day simple moving average is $0.91.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Thursday, August 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.17. As a group, sell-side analysts predict that Jasper Therapeutics will post -1.47 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Renaissance Technologies LLC boosted its position in Jasper Therapeutics by 9.0% during the 4th quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock worth $416,000 after acquiring an additional 18,683 shares during the period. Geode Capital Management LLC grew its stake in Jasper Therapeutics by 61.9% during the 4th quarter. Geode Capital Management LLC now owns 211,857 shares of the company’s stock valued at $388,000 after acquiring an additional 81,002 shares in the last quarter. Knott David M Jr increased its holdings in shares of Jasper Therapeutics by 5.8% in the 4th quarter. Knott David M Jr now owns 181,389 shares of the company’s stock valued at $332,000 after purchasing an additional 10,000 shares during the period. Marshall Wace LLP acquired a new position in shares of Jasper Therapeutics in the 2nd quarter valued at about $281,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Jasper Therapeutics in the fourth quarter worth approximately $256,000. 79.85% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages recently issued reports on JSPR. Royal Bank Of Canada set a $3.00 target price on Jasper Therapeutics and gave the stock a “sector perform” rating in a report on Friday, May 15th. TD Cowen downgraded Jasper Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th. Wall Street Zen lowered Jasper Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Finally, Piper Sandler initiated coverage on Jasper Therapeutics in a report on Wednesday. They set an “overweight” rating and a $2.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $8.17.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.